-
Next year, submit a new indication application for the blockbuster IL-4/IL-13 inhibitor phase 3 clinical report again
Time of Update: 2021-11-16
Today, Regeneron and Sanofi announced that Dupixent, a blockbuster IL-4/IL-13 inhibitor, reached the dual primary endpoint in the second clinical trial for the treatment of eosinophilic esophagitis (EoE) .
-
Why is the poisonous "Cruise officinalis" in Yang Guo's body really a medicine?
Time of Update: 2021-11-16
Figure 3 Alkaloids in GelsemiumPharmacological studies have proved that Gelsemium alkaloids have the effects of analgesia, immune regulation and tumor growth inhibition, and they are clinically used to treat cancer pain, sciatica, smooth muscle colic and other pains, as well as eczema, furuncle carbuncle, and psoriasis.
-
Merck/Ridgeback oral drug molnupiravir enters rolling review in EU
Time of Update: 2021-11-16
The subjects are included in the laboratory test confirmed as mild to moderate COVID -19 non-hospitalized adult patients (age ≥18 years) who were not vaccinated against SARS-CoV-2, had at least one risk factor related to adverse disease outcome, and developed symptoms within 5 days before randomization .
-
"Nobel Prize in Medicine"-Galen Prize will be announced soon!
Time of Update: 2021-11-16
There are three main awards for the Galen Award: Best Pharmaceutical Agent, Best Biotechnology Product, and Best Medical Technology .
In 2012 and 2014, the Galen Prize was awarded to hepatitis C treatment drugs .
-
Pioglitazone Hydrochloride Tablets, a wholly-owned subsidiary of Kangen Bay, passed the consistency evaluation of generic drugs
Time of Update: 2021-11-16
On October 20, Kang Enbei issued an announcement stating that its wholly-owned subsidiary Hangzhou Kang Enbei received the "Drug Supplementary Application Approval Notice" approved and issued by the National Medical Products Administration, and pioglitazone hydrochloride tablets passed the consistency evaluation of generic drugs .
-
The official topping of the Lvgu sugar drug production base is expected to benefit Alzheimer's patients worldwide
Time of Update: 2021-11-16
It is committed to ensuring production quality and In line with international standards, as China's first production base for exporting sugar drugs to the world, it carries the important mission of the internationalization of China's original drugs, which is expected to benefit patients with Alzheimer's disease (AD) worldwide .
-
Junshi Biology JS019 Injection Obtained the Notification of Acceptance of Drug Clinical Trial Application
Time of Update: 2021-11-16
(hereinafter referred to as " Suzhou Keboruijun") received the "Notice of Acceptance" approved and issued by the State Drug Administration, and the clinical trial application for JS019 injection (project code "JS019") was accepted .
-
BeiGene's BTK-targeted protein degrading agent is accepted for clinical application in China
Time of Update: 2021-11-16
▲CDAC platform of BeiGene (Source: BeiGene Public PPT)Public information shows that BGB-16673 is a protein degradation agent targeting Bruton's tyrosine kinase (BTK) .
-
Changes in the treatment of nAMD!
Time of Update: 2021-11-16
On October 22, Roche announced that the FDA has approved its new drug delivery device Susvimo (Ranibizumab injection 100mg/ml) for the treatment of at least two anti-VEGF therapies for wet age-related macular degeneration (nAMD).
-
The first phase Ⅲ clinical study of Kang Ning Jereh double-antibody KN046 completes all patients enrollment
Time of Update: 2021-11-16
ENREACH-LUNG-01 is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study of KN046 combined with platinum-containing chemotherapy in patients with advanced unresectable or metastatic squamous non-small cell lung cancer for evaluation The safety and effectiveness of KN046 combined chemotherapy at a dose of 5 mg/kg was led by Professor Zhou Caicun from Shanghai Pulmonary Hospital as the main investigator.
-
Big moves continue!
Time of Update: 2021-11-16
On October 10th, Zhang Lianshan, Senior Deputy General Manager and President of Global R&D of Hengrui Pharmaceuticals, stated at the 2021 Biopharmaceutical Process Development Summit BPD that China’s innovative drugs are an inevitable choice to “go global” .
-
Pioneer Pharmaceuticals completes the first patient administration in the Phase III clinical trial of Prokalutamide in the treatment of hospitalized patients with new crowns in the United States
Time of Update: 2021-11-16
Tong Youzhi, Founder, Chairman and CEO of Pioneer Pharmaceuticals, said: "I am very pleased to announce that the registered Phase III clinical trial of Prokalamide for the treatment of hospitalized patients with severe new coronary disease has completed the first patient enrollment in the United States .
-
Many provinces announced: cancel this year's licensed pharmacist exam
Time of Update: 2021-11-16
According to the relevant requirements of the Hunan Provincial Department of Epidemic Prevention and Control and the relevant regulations of Hunan Personnel Examination and Epidemic Prevention and Control, people with a history of residence in the following areas are not allowed to go to the test site to participate in the public recruitment examination of public institutions in Hunan Province on October 23, 2021 and Hunan Province’s 2021 survey Qualification examination for design, urban and rural planners, licensed pharmacists:1.
-
Double the ORR!
Time of Update: 2021-11-16
The data released at the CSCO annual meeting further confirmed that KN046 combined with albumin paclitaxel/gemcitabine has excellent efficacy in the first-line treatment of unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma, and the objective response rate (ORR) is more than doubled compared with traditional chemotherapy.
-
The world's first new crown "oral medicine" will be available. Why is the vaccine, neutralizing antibody, and domestic small molecule oral medicine hit hard?
Time of Update: 2021-11-16
It is reported that among local companies, except Junshi Bio/Lilly's new crown neutralizing antibody drug (JS016), which has been approved for application in many major markets around the world .
-
Is the new crown vaccine not "red" anymore?
Time of Update: 2021-11-16
Unlike the cooperation between Tibet Pharmaceuticals and Sri Lanka Microbiology, the new coronavirus vaccine (PIV-5 carrier) licensing cooperation agreement of Changchun High-tech, Beike Biotech and Guangzhou Sianxin Biotech is a connected transaction .
-
Chengdu Beite's 3 major new products will be approved
Time of Update: 2021-11-16
Recently, Chengdu Better (including its subsidiaries) has 3 new generic drugs that have been classified for production and entered the administrative approval stage, namely Futhiaxetine Hydrobromide Tablets, Lenvatinib Mesylate Capsules and Ipratropium Bromide.
-
CD73 monoclonal antibody!
Time of Update: 2021-11-16
After this clinical approval, Jacos Pharmaceuticals will start a phase 1/2a clinical trial for patients with solid tumors in the United States .
-
Director and Deputy General Manager Li Huajun of Si Taili resigned
Time of Update: 2021-11-16
On October 11, Stellite issued an announcement stating that the board of directors had recently received a written resignation report from the company’s director and deputy general manager, Mr.
After resignation, he will not hold any position in the company.
-
Roche's new crown oral drug failed phase II clinical progress and how is the clinical progress of the other 4 companies
Time of Update: 2021-11-16
Recently, Roche and Atea Pharmaceuticals announced that their new crown oral drug AT-527 global phase II trial MOONSONG did not meet the primary endpoint .
The clinical failure of Roche/Atea's new crown oral drug is right.
